Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley(National Cancer Institute), Jeffrey Schlom(National Cancer Institute), Vittore Cereda(National Institutes of Health), Lisa Skarupa(National Institutes of Health), Jack P. Higgins(Molecular Templates (United States)), William L. Dahut(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Ravi A. Madan(National Cancer Institute), Susan Halabi(Duke Medical Center), Howard L. Parnes(National Institutes of Health), Philip M. Arlen(Dana-Farber Cancer Institute), Mary Pazdur(National Institutes of Health), Jacquin Jones(National Institutes of Health), Matteo Vergati(National Institutes of Health), Diane J. Poole(National Institutes of Health), Clara Chen(National Institutes of Health Clinical Center), Elizabeth C. Jones(National Institutes of Health Clinical Center), Kwong-Yok Tsang(National Cancer Institute), James W. Hodge(National Cancer Institute)
Cited by 298
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|973
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
|Journal of Clinical Oncology|1999|893